tbuckley/cabot-search huggingface dataset:
Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279).
Authors: Amit Bahl, Susan Masson, Zafar Malik, Alison J Birtle, Santhanam Sundar, Robert J Jones, Nicholas David James, Malcolm David Mason, Satish Kumar, David Bottomley, Anna Lydon, Simon Chowdhury, James Wylie, Johann Sebastian De Bono
Journal: Journal of Clinical Oncology (2012)

44 Background: Cabazitaxel, a tubulin-binding taxane, improved survival in mCRPC in the TROPIC trial. Notable toxicities were neutropenia and diarrhoea. We report interim safety and QOL data from a single arm multicentre open label study providing early access to cabazitaxel in the UK. Methods: Patients recruited from 12 centres received cabazitaxel 25mg/m 2 intravenously every 3 weeks and prednisolone 10mg daily. Safety assessments were performed before each cycle. Patients completed the EQ-5D questionnaire and health state visual analogue scale (VAS) at baseline and at alternate cycles. Patients recruited before March 31 st 2011 are included in the safety analysis. QOL data collected before July 31 st 2011 at baseline (n=62), cycle 2 (n=50) and cycle 4 (n=26) are included. Results: Median age was 68 years; 24% were aged over 75 years. 93% had bone metastases. 50% had experienced disease progression during or within 3 months of docetaxel and the remaining 50% within 3-6 months. A median of 3 cycles of cabazitaxel were completed with 99% relative dose intensity. 83% continued cabazitaxel at the time of safety analysis. 7 patients stopped before completing the full course, 5 of these were due to disease progression. One treatment related death occurred within 30 days of the last cabazitaxel infusion (2.4%). 85% of patients received granulocyte-colony stimulating factor prophylaxis from cycle 1. The proportion of patients reporting no pain or discomfort increased between baseline, cycle 2 and cycle 4 (22.6% to 38% to 50%). Anxiety and depression, mobility and self-care scores from EQ-5D were stable. Median VAS health state increased from baseline (75%) to cycle 4 (79%). Conclusions: Improvements in pain control and health states were reported during early stages of cabazitaxel treatment. Other EQ-5D QOL measures were stable. Severe toxicity was rare. Results will be updated from final analysis in late 2011. [Table: see text]
Service Rhymes.
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Article Information
Journal: JAMA Network Open (2021)

Alberto Benussi, MD; Enrico Premi, MD; Stefano Gazzina, MD; Chiara Brattini, MSc; Elisa Bonomi, MSc; Antonella Alberici, MD; Lize Jiskoot, PhD; John C. van Swieten, PhD; Raquel Sanchez-Valle, PhD; Fermin Moreno, MD, PhD; Robert Laforce, MD, PhD; Caroline Graff, MD, PhD; Matthis Synofzik, MD; Daniela Galimberti, PhD; Mario Masellis, MD, PhD; Carmela Tartaglia, MD; James B. Rowe, MD, PhD; Elizabeth Finger, MD; Rik Vandenberghe, MD, PhD; Alexandre de Mendonça, MD, PhD; Fabrizio Tagliavini, MD; Isabel Santana, MD, PhD; Simon Ducharme, MD; Chris R. Butler, PhD; Alexander Gerhard, MD; Johannes Levin, MD; Adrian Danek, MD; Markus Otto, MD; Giovanni Frisoni, MD, PhD; Roberta Ghidoni, PhD; Sandro Sorbi, MD, PhD; Isabelle Le Ber, MD, PhD; Florence Pasquier, MD, PhD; Georgia Peakman, BSc; Emily Todd, BSc; Martina Bocchetta, PhD; Jonathan D. Rohrer, PhD; Barbara Borroni, MD; Genetic FTD Initiative (GENFI); Sònia Afonso; Maria Rosario Almeida; Sarah Anderl-Straub; Christin Andersson; Anna Antonell; Silvana Archetti; Andrea Arighi; Mircea Balasa; Myriam Barandiaran; Nuria Bargallò; Robart Bartha; Benjamin Bender; Luisa Benussi; Maxime Bertoux; Anne Bertrand; Valentina Bessi; Giuliano Binetti; Sandra Black; Sergi Borrego-Ecija; Jose Bras; Alexis Brice; Rose Bruffaerts; Agnès Camuzat; Marta Cañada; Paola Caroppo; David Cash; Miguel Castelo-Branco; Olivier Colliot; Rhian Convery; Thomas Cope; Maura Cosseddu; Vincent Deramecourt; Marìa de Arriba; Giuseppe Di Fede; Alina Dìez; Diana Duro; Chiara Fenoglio; Camilla Ferrari; Catarina B Ferreira; Nick Fox; Morris Freedman; Giorgio Fumagalli; Aurélie Funkiewiez; Alazne Gabilondo; Roberto Gasparotti; Serge Gauthier; Stefano Gazzina; Giorgio Giaccone; Ana Gorostidi; Caroline Greaves; Rita Guerreiro; Carolin Heller; Tobias Hoegen; Begoña Indakoetxea; Vesna Jelic; Hans-Otto Karnath; Ron Keren; Gregory Kuchcinski; Tobias Langheinrich; Thibaud Lebouvier; Maria João Leitão; Albert Lladò; Gemma Lombardi; Sandra Loosli; Carolina Maruta; Simon Mead; Lieke Meeter; Gabriel Miltenberger; Rick van Minkelen; Sara Mitchell; Katrina Moore; Benedetta Nacmias; Jennifer Nicholas; Linn Öijerstedt; Jaume Olives; Sebastien Ourselin; Alessandro Padovani; Jessica Panman; Janne M Papma; Michela Pievani; Yolande Pijnenburg; Cristina Polito; Sara Prioni; Catharina Prix; Rosa Rademakers; Veronica Redaelli; Daisy Rinaldi; Tim Rittman; Ekaterina Rogaeva; Adeline Rollin; Pedro Rosa-Neto; Giacomina Rossi; Martin Rossor; Beatriz Santiago; Dario Saracino; Sabrina Sayah; Elio Scarpini; Sonja Schönecker; Harro Seelaar; Elisa Semler; Rachelle Shafei; Christen Shoesmith; Miguel Tábuas-Pereira; Mikel Tainta; Ricardo Taipa; David Tang-Wai; David L Thomas; Paul Thompson; Hakan Thonberg; Carolyn Timberlake; Pietro Tiraboschi; Emily Todd; Philip Van Damme; Mathieu Vandenbulcke; Michele Veldsman; Ana Verdelho; Jorge Villanua; Jason Warren; Carlo Wilke; Ione Woollacott; Elisabeth Wlasich; Henrik Zetterberg; Miren Zulaica
Empire Rheumatism Council: Royal President's Address at Mansion House
Authors: William Willcox, Joseph Burn, Mr Lewis, Walter Fisher, W Copeman, Mrs Copeman, K Lewis, A Mcmahon, William Wilcox, C Griffiths, Allan Powell, C Thornton, George Macdonogh, Mr Grantham, K Pro- Fessor, L Davidson, Hon Medical Secratary, Walter Kinnear, Robert Woods, Mr Fisher, F Mr, C Izard, F Buckley, E Chapman, M Mr, Hobbs Dudley
Journal: Annals of the Rheumatic Diseases (1939)

The Lord Mayor, opening the meeting, said: " It is with great pleasure, Your Royal Highness, that I welcome the honour of your presence at the Mansion House as Pre3ident of the Empire Rheumatism Council on a mission of humanity and of hope to the sufferers from Rheumatic Disease."The Royal House of our Empire has worked nobly to justify the oldest and the most honourable title given to Kings and Princes: that of being ' Shepherds of their People,' taking a solicitous interest in good movements for their welfare, and especially in efforts to protect them from the ravages of disease.
Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis.
Authors: B Stewart, J Zabner, A P Shuber, M J Welsh, P B McCray
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Since its introduction in 1959, the sweat test has remained the "gold standard" diagnostic test for cystic fibrosis (CF). It is apparent that CF encompasses a wide spectrum of disease, from meconium ileus and severe respiratory compromise in infants to the presentation of mild pulmonary symptoms and no evidence of gastrointestinal disease in adults. In patients with lung disease that might otherwise be consistent with CF, normal sweat chloride (Cl-) values have tended to exclude the diagnosis. In this report we describe two patients from two families with the compound heterozygotic CF mutations delta F508/3849 + 10 kb C-->T. These patients had mild manifestations of disease, including clinical pancreatic sufficiency (normal growth without pancreatic enzyme supplementation) and absence of azoospermia. Sweat Cl- values were in the normal range. However, both patients developed bronchiectasis, progressive obstructive lung disease, and colonization with Pseudomonas. The diagnosis of CF was made using nasal transepithelial voltage measurements and genotyping. These cases emphasize the need to maintain a high index of suspicion of CF in atypical cases, and to pursue alternative diagnostic tests to confirm a diagnosis of CF suspected on clinical grounds, despite normal sweat test results.
Reformulated Omnopon
Authors: D Robson
Journal: BMJ (1992)

however, is open to error.A considerable educational effort would be required to alter established prescribing habits.To complicate matters further, the title of the products on the datasheet does not reflect the name printed on our stock of the reformulated product.Omnopon Paediatric is actually packaged and labelled as Omnopon 10 with no reference to paediatric on the box.We believe that the risk of the wrong strength of Omnopon being prescribed and administered is great and does not warrant its continued use.
Editorial: Toxic megacolon may complicate Crohn's disease.
Journal: BMJ (1975)

Prepared for a Disaster?The Moorgate tube-train disaster was an incident which created difficulties from every conceivable angle and confirmed many of the problems to be experienced in disaster manage- ment generally.On page 727 the medical staff concerned with the handling of this most unfortunate incident describe some of the problems they encountered.From the outset it was difficult to assess the magnitude of the accident, and particular problems were experienced in gaining access to the casualties.Lighting and ventilation were required in the confined area of the rescue, and the equipment providing these facilities, together with the cutting equipment, generated noise which in turn added to the difficulties of communication underground.In spite of these and many other problems 74 live patients were evacuated in 13 hours, including one who required an on-site amputation to effect her release.An emergency resuscitation area was established on the under- ground platform, and the efficiency of the sorting and re- suscitation by the medical teams was reflected by the fact that only two casualties reaching hospital were dead on arrival and by the absence of airway problems among all those who were alive.
"'CHRISTIAN SCIENCE' AND SLOPPY THINKING"
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nitric Oxide and Peroxynitrite Production in Ocular Inflammation
Authors: Janice Benson Allen, Teresa Keng, Christopher Privalle
Journal: Environmental Health Perspectives (1998)

Recent studies have implicated nitric oxide and peroxynitrite in the pathogenesis of many diseases, such as septic shock, arthritis, lung disease, and atherosclerosis.Nitric oxide ('NO) exerts many diverse effects on vascular tone, affecting neurotransmission and cellular cytotoxicity/communication.Our laboratory and others have documented a proinflammatory role for 'NO in ocular inflammation.Uveitis, which is an inflammation of the highly vascular uveal tract in the eye, is a debilitating condition that can lead to visual impairment and blindness.It is characterized by acute, recurrent, or persistent inflammation with disruption of the blood-aqueous barrier and is accompanied by protein leakage and leukocyte infiltration into the aqueous humor and anterior chamber.Systemic injection of endotoxin into mice and rats, or intraocular injection of endotoxin into mice, rats, and rabbits induces acute uveitis, which clinically and histologically resembles acute anterior uveitis in humans.These models facilitate the study of pathogenic mechanisms that contribute to ocular inflammation.In addition to 'NO, superoxide anion radicals (02'-), and peroxynitrite (ONOO-), the products of the reaction between 'NO and 02'-, are also implicated in uveitis.The role of peroxynitrite in ocular inflammation is still largely unknown.Characterization of the roles of these important uveitic mediators in the ocular inflammatory response will provide information critical to the understanding of the pathogenesis of intraocular inflammation so that more effective therapeutic intervention(s) can be developed.
Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.
Authors: Michael Lam, Allan Andresson Lima Pereira, Jonathan M. Loree, Shailesh M Advani, Michael J. Overman, Amber Johnson, Vijaykumar Holla, Yekaterina Khotskaya, Nora Sylvia Sanchez, Funda Meric-Bernstam, Scott Kopetz, Shubham Pant
Journal: Journal of Clinical Oncology (2018)

3522 Background: The benefits of matching targeted treatments to aberrations identified by molecular profiling (MP) is unclear. Outcomes in phase 1 settings have been traditionally reported across tumor histologies. We report outcomes based on a metastatic colorectal cancer (mCRC) population. Methods: Patients (pts) with mCRC receiving at least one dose of treatment on a phase 1 study were annotated for variants detected by MP. A precision oncology decision support (PODS) team determined variant function and actionability. A matched therapy (MT) was defined as allocation to a novel agent that targeted the aberration or predicted pathway deemed actionable by PODS. Progression-free survival (PFS) was estimated using the Kaplan-Meier method. A Cox proportional hazards model was used to estimate hazard ratios (HR). Results: A total of 370 patients enrolled onto 467 phase 1 trials were identified from January 2012 to April 2017. 106 enrolments were assigned to MT. Pts with microsatellite instability-high (MSI-H), BRAFV600E, PIK3CA mutation were more likely to be assigned a MT, while left-sided tumors and RAS mutant patients were less likely to be treated with a MT. Molecularly-targeted regimens (MTR) were utilized more frequently in MT while immune-targeting MTR was more common in non-MT. BRAFV600E mutations and HER2 amplification/overexpression made up 44.3% of MT. There was a significant difference in PFS between the MT vs non-MT group (HR 0.65, 95% CI 0.51-0.83, p = 0.016) in univariate analysis. The 6-month PFS probability was 31% (95% CI; 23-41%) versus 13% (95% CI; 10-17%) respectively. Other significant factors in univariate analysis associated with longer PFS were MSI-H, BRAFV600E and use of a regimen containing cytotoxic chemotherapy while RAS mutations were associated with shorter PFS. In multivariate analysis, after correcting for mutation status, allocation to a MT was associated with improved PFS (HR = 0.72, 95% CI 0.50-0.99, p = 0.043). Conclusions: Matching clinical trial enrollment to MP based on dedicated decision support is associated with improved outcomes in mCRC patients. The MT strategy is still hampered by a limited number of actionable variants, and is driven by a small number of active MTs.
Parasite screening and treatment among Indochinese refugees. Cost-benefit/utility and the General Health Policy Model
Authors: J. P. Anderson
Journal: JAMA (1985)

The General Health Policy Model and the Quality of Well-being scale are used to describe a "cost-benefit/utility" evaluation of a screening and treatment program for intestinal parasites among Indochinese refugees in the United States. Cost-benefit/utility analysis subsumes conventional cost-effectiveness by explicitly adding social utility factors to the dollar dimension. Using actual data on parasite prevalence and program costs from one screening project and estimated figures for other factors, this article demonstrates calculation of the cost-benefit/utility outcome measure, dollars per well-year. Dollars per well-year for parasite screening are calculated for a number of examples. Further analysis and final conclusions on the worth of parasite screening and treatment programs await more reliable data for some terms of the developed model. (<i>JAMA</i>1985;253:2229-2235)
Ethics
Authors: E. D. Pellegrino
Journal: JAMA (1993)

The right of patients and their surrogates to participate in medical decisions is now firmly established in law and ethics. What is currently being debated is how far this right of participation extends. The controversy arises from several recent court cases in which surrogates have demanded treatments physicians have judged medically futile. As a result, several new questions are at issue: Are there limits to the patient's right of participation? Are there conditions under which physicians may be ethically obliged to refuse to provide, or even to offer, specific treatments? Who defines treatment futility and by what criteria? The right of participation was first asserted as a patient's right to refuse even life-sustaining treatments.<sup>1,2</sup>Fifteen years ago in the<i>Quinlan</i>case,<sup>3</sup>this was extended to include the right of surrogates of incompetent patients to refuse life-support measures even if a physician judged them medically and ethically appropriate. This
Pyrethrum Flowers and Pyrethroid Insecticides
Authors: John E. Casida
Journal: Environmental Health Perspectives (1980)

The natural pyrethrins from the daisy-like flower, Tanacetum or Chrysanthemum cinerariifolium, are nonpersistent insecticides of low toxicity to mammals. Synthetic analogs or pyrethroids, evolved from the natural compounds by successive isosteric modifications, are more potent and stable and are the newest important class of crop protection chemicals. They retain many of the favorable properties of the pyrethrins.
Asthma and Gastroesophageal Reflux
Authors: Donald O. Castell
Journal: JAMA (1977)

<h3>To the Editor.—</h3> The article by Dr Mays inThe Journal(236:2626,1976) raises the concept that in patients with chronic gastroesophageal (GE) reflux, pulmonary disease may develop as a result. Clinicians have subjectively suspected such an association because patients with documented reflux and coincidental lung disease occasionally will complain of nocturnal cough. There is great potential for acid reflux to occur at night when the patient is supine, and one can speculate that aspiration of refluxed material is more likely during sleep. It is important that we recognize that the apparent relationship between these two entities is more of a "clinical feeling" than having been established by meaningful objective observations, and that although it seems quite likely that there is an important relationship present, we must bear in mind that subjective clinical impressions frequently turn out to be less than factual when objectively tested. It is most disturbing that Mays
The role of methanethiol in the pathogenesis of hepatic encephalopathy
Authors: H Blom
Journal: Hepatology (1991)

Mixed disulfides of methanethiol represent a relative estimate for an exposure to methanethiol. The concentrations of methanethiol-mixed disulfides, methionine, 4-methylthio-2-oxobutyrate and ammonia were measured in patients with different stages of hepatic encephalopathy, in patients with chronic kidney failure and in healthy subjects. In patients with hepatic encephalopathy, the mean serum concentrations of all these compounds were elevated. However, the elevations of methanethiol-mixed disulfides were small and partly caused by decreased renal function. In addition, the levels of methanethiol-mixed disulfides did not differ significantly between the different grades of hepatic encephalopathy. The concentrations of methanethiol-mixed disulfides were substantially lower than those previously observed in healthy subjects after an oral methionine load or in a patient with a deficiency in methionine adenosyltransferase, the latter without causing encephalopathy. We concluded that the role of methanethiol in the pathogenesis of hepatic encephalopathy is probably minor, if not insignificant. In the patients with hepatic encephalopathy, a significant correlation was found between the concentrations of methionine and 4-methylthio-2-oxobutyrate and between 4-methylthio-2-oxobutyrate and methanethiol-mixed disulfides, supporting the theory that methanethiol is formed by way of the methionine transamination pathway. Evidence is provided that, besides the methionine transsulfuration pathway, the transamination pathway is also impaired in patients with hepatic encephalopathy. (HEPATOLOGY 1991;13:445–454.)
Continuing Education Courses for Physicians
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
Authors: Yohann Loriot, Gabriel Perlemuter, David Malka, Frédérique Penault-Llorca, Valérie Boige, Eric Deutsch, Christophe Massard, Jean Pierre Armand, Jean-Charles Soria
Journal: Nature Reviews Clinical Oncology (2009)
TCT-811 High Syntax score and left main percutaneous coronary intervention in high risk patients. Results at 10-year follow-up
Authors: Ignacio Sanchez-Perez, Jesus Piqueras-Flores, Alfonso Jurado-Román, María Thiscal López Lluva, Natalia Pinilla-Echeverri, Ramón Maseda Uriza, Manuel Marina-Breysse, Fernando Lozano
Journal: Journal of the American College of Cardiology (2017)